Practical recommendations for the management of diabetes in patients with COVID-19.

Publisher: The Lancet, Diabetes & Endocrinology Country of Publication: England NLM ID: 101618821 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-8595 (Electronic) Linking ISSN: 22138587 NLM ISO Abbreviation: Lancet Diabetes Endocrinol Subsets: MEDLINE

Original Publication: London : The Lancet, Diabetes & Endocrinology, [2013]-

Pandemics*; Betacoronavirus/*pathogenicity ; Coronavirus Infections/*physiopathology ; Diabetes Mellitus, Type 1/*drug therapy ; Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemic Agents/*adverse effects ; Pneumonia, Viral/*physiopathology; COVID-19 ; Comorbidity ; Contraindications, Drug ; Coronavirus Infections/therapy ; Diabetes Mellitus, Type 1/physiopathology ; Diabetes Mellitus, Type 2/physiopathology ; Humans ; Hypoglycemic Agents/administration & dosage ; Multiple Organ Failure/chemically induced ; Multiple Organ Failure/physiopathology ; Pneumonia, Viral/therapy ; Practice Guidelines as Topic ; Respiratory Distress Syndrome/chemically induced ; Respiratory Distress Syndrome/physiopathology ; SARS-CoV-2

Diabetes is one of the most important comorbidities linked to the severity of all three known human pathogenic coronavirus infections, including severe acute respiratory syndrome coronavirus 2. Patients with diabetes have an increased risk of severe complications including Adult Respiratory Distress Syndrome and multi-organ failure. Depending on the global region, 20-50% of patients in the coronavirus disease 2019 (COVID-19) pandemic had diabetes. Given the importance of the link between COVID-19 and diabetes, we have formed an international panel of experts in the field of diabetes and endocrinology to provide some guidance and practical recommendations for the management of diabetes during the pandemic. We aim to briefly provide insight into potential mechanistic links between the novel coronavirus infection and diabetes, present practical management recommendations, and elaborate on the differential needs of several patient groups.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)

Comment in: Diabet Med. 2020 Jul;37(7):1214-1216. (PMID: 32421882)
Comment in: Lancet Diabetes Endocrinol. 2020 Aug;8(8):666-667. (PMID: 32707108)
Comment in: Lancet Diabetes Endocrinol. 2020 Aug;8(8):666. (PMID: 32707109)
Comment in: Lancet Diabetes Endocrinol. 2020 Aug;8(8):667-668. (PMID: 32707110)
Comment in: Lancet Diabetes Endocrinol. 2020 Aug;8(8):668. (PMID: 32707111)
Comment in: Lancet Diabetes Endocrinol. 2020 Aug;8(8):669. (PMID: 32707112)
Comment in: Lancet Diabetes Endocrinol. 2020 Aug;8(8):669-670. (PMID: 32707113)

N Engl J Med. 2020 May 7;382(19):1787-1799. (PMID: 32187464)
Mol Cell Endocrinol. 2009 Apr 29;302(2):193-202. (PMID: 18948167)
Nutrients. 2020 Jan 16;12(1):. (PMID: 31963293)
Diabetes Res Clin Pract. 2020 Apr;162:108125. (PMID: 32224164)
Heart Vessels. 2017 May;32(5):618-627. (PMID: 28013371)
J Diabetes Res. 2020 Feb 27;2020:5214751. (PMID: 32190699)
Lancet. 2020 Mar 28;395(10229):1063-1077. (PMID: 32145185)
Nature. 2013 Mar 14;495(7440):251-4. (PMID: 23486063)
Lancet Respir Med. 2020 Apr;8(4):e21. (PMID: 32171062)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Pulmonology. 2020 May - Jun;26(3):123-129. (PMID: 31787563)
Acta Diabetol. 2010 Sep;47(3):193-9. (PMID: 19333547)
Int J Mol Sci. 2017 Mar 05;18(3):. (PMID: 28273875)
Lancet. 2020 Apr 11;395(10231):1225-1228. (PMID: 32178769)
Int J Infect Dis. 2020 Mar;92:208-213. (PMID: 31978583)
Adv Nutr. 2016 Jan 15;7(1):66-75. (PMID: 26773015)
Lancet. 2015 Sep 5;386(9997):964-73. (PMID: 26369473)
Crit Care Med. 2013 Feb;41(2):580-637. (PMID: 23353941)
Acta Diabetol. 2020 Jun;57(6):759-764. (PMID: 32249357)
Sci Rep. 2017 Aug 22;7(1):9110. (PMID: 28831119)

0 (Hypoglycemic Agents)

Date Created: 20200427 Date Completed: 20200622 Latest Revision: 20230322

20240628

PMC7180013

10.1016/S2213-8587(20)30152-2

32334646